Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata

• Status: Completed
• Trial end date: 2023-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value <0.05 as significant, was used.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Combined Military Hospital Abbottabad
• Treatments: Clobetasol; Tacrolimus

Criteria

Inclusion Criteria:

• Patients age 20 to 50 years

• Both male and female

• Duration of illness less than 2 months

• those who never received any treatment before

Exclusion Criteria:

• Patients having duration of alopecia greater than 2 months

• Atypical alopecia areata i.e., Alopecia universalis etc

• Hypersensitivity history to topical corticosteroids or tacrolimus

• patients taking any systemic immune suppression

• pregnancy/lactation